Virological assessment of hospitalized cases of coronavirus disease 2019
Open Access
- 8 March 2020
- preprint content
- other
- Published by Cold Spring Harbor Laboratory
Abstract
Coronavirus disease 2019 (COVID-19) is an acute respiratory tract infection that emerged in late 20191,2. Initial outbreaks in China involved 13.8% cases with severe-, and 6.1% with critical courses3. This severe presentation corresponds to the usage of a virus receptor that is expressed predominantly in the lung2,4. By causing an early onset of severe symptoms, this same receptor tropism is thought to have determined pathogenicity but also aided the control of severe acute respiratory syndrome (SARS) in 20035. However, there are reports of COVID-19 cases with mild upper respiratory tract symptoms, suggesting a potential for pre- or oligosymptomatic transmission6-8. There is an urgent need for information on body site - specific virus replication, immunity, and infectivity. Here we provide a detailed virological analysis of nine cases, providing proof of active virus replication in upper respiratory tract tissues. Pharyngeal virus shedding was very high during the first week of symptoms (peak at 7.11 × 108 RNA copies per throat swab, day 4). Infectious virus was readily isolated from throat- and lung-derived samples, but not from stool samples in spite of high virus RNA concentration. Blood and urine never yielded virus. Active replication in the throat was confirmed by viral replicative RNA intermediates in throat samples. Sequence-distinct virus populations were consistently detected in throat- and lung samples of one same patient. Shedding of viral RNA from sputum outlasted the end of symptoms. Seroconversion occurred after 6-12 days, but was not followed by a rapid decline of viral loads. COVID-19 can present as a mild upper respiratory tract illness. Active virus replication in the upper respiratory tract puts prospects of COVID-19 containment in perspective.Keywords
This publication has 23 references indexed in Scilit:
- Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, ChinaThe New England Journal of Medicine, 2020
- SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected PatientsThe New England Journal of Medicine, 2020
- Transmission of 2019-nCoV Infection from an Asymptomatic Contact in GermanyThe New England Journal of Medicine, 2020
- First Case of 2019 Novel Coronavirus in the United StatesThe New England Journal of Medicine, 2020
- A Novel Coronavirus from Patients with Pneumonia in China, 2019The New England Journal of Medicine, 2020
- Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study GroupPublished by Cold Spring Harbor Laboratory ,2020
- The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cellsPublished by Cold Spring Harbor Laboratory ,2020
- Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCREurosurveillance, 2020
- Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infectionsEurosurveillance, 2012
- The Epidemiology of Severe Acute Respiratory Syndrome in the 2003 Hong Kong Epidemic: An Analysis of All 1755 PatientsAnnals of Internal Medicine, 2004